French healthcare company Sanofi S.A. (Euronext Paris:SAN) (Nasdaq:SNY) announced on Friday that the National Medical Products Administration (NMPA) in China has approved Dupixent (dupilumab) as an add-on maintenance treatment for adults with uncontrolled chronic obstructive pulmonary disease (COPD) characterised by raised blood eosinophils.
Dupilumab is being jointly developed by Sanofi and US biotechnology company Regeneron Pharmaceuticals Inc (Nasdaq:REGN) under a global collaboration agreement.
The approval in China follows EU approval of Dupixent for adults with COPD with raised blood eosinophils. The decision was based on two landmark phase 3 studies showing Dupixent significantly reduced exacerbations, improved lung function, and also improved health-related quality of life.
COPD is the most prevalent chronic respiratory disease in China and is a priority within the government's Healthy China 2030 public health plan. Dupixent is now approved in four indications across respiratory and dermatological diseases in China.
Genprex partners with University of Michigan to explore Reqorsa for lung cancer treatment
United Therapeutics reaches milestone with 500th lung transplant via ex vivo lung perfusion service
Foresee Pharmaceuticals completes linvemastat (FP-020) phase clinical study in Australia
HUTCHMED's TAGRISSO plus ORPATHYS shows promise in lung cancer treatment
GSK reports positive Phase III results for depemokimab in chronic rhinosinusitis with nasal polyps
GE HealthCare expands AI-enabled enterprise imaging with Blackford integration
PureTech Health highlights progress in IPF research and LYT-100 at CHEST 2024
MediLink enters clinical trial collaboration and supply agreement with Amgen
Innovent Biologics partners with Jiangsu Aosaikang Pharmaceutical for lung cancer treatment
Genprex research collaborators to present positive data on Reqorsa Gene Therapy at SITC 2024
hVIVO reports positive results from RSV antiviral human challenge trial